


Supplementary information for

**Adenosine 2a receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization**

Grace L. Edmunds, Carissa C.W. Wong, Rachel Ambler, Emily J. Milodowski, Hanin Alamir, Stephen J. Cross, Gabriella Galea, Christoph Wülfing, David J. Morgan



Supplementary figures 1 and 2  
Supplementary movies 1 through 4  
Figure source files for figures 2 through 7

## Supplementary Figures



### Supplementary figure 1 – supporting data for A2aR antagonist treatment

**a** CD4<sup>+</sup>CD25<sup>+</sup> TIL from RencaHA tumor-bearing BALB/c mice were co-cultured with naïve CD8<sup>+</sup> CL4 T cells and irradiated mature dendritic cells and K<sup>d</sup>HA peptide with or without the A2aR antagonist ZM 241385 at 1.25  $\mu$ M for 3 days. <sup>3</sup>H-thymidine incorporation (cpm) is shown as mean  $\pm$  SEM. N=10 mice over two experiments (paired t-test). **b** FACS gating strategy for the identification of CD8<sup>+</sup> TIL in sequential gates as indicated from the top to the bottom panel. **c** Percentage of CD8<sup>+</sup> TIL from RencaHA tumor-bearing BALB/c mice treated with or without the A2aR antagonist ZM 241385 at 10 mg/kg i.p. expressing TIM3 are given as a function of tumor size as mean  $\pm$  SEM for N=6 experiments.



### Supplementary figure 2 – Supporting technical data for *in vivo* tumor growth experiments upon adoptive CTL transfer

**a** Numbers of mice used across the different parts of the experiments in Figs. 4 and 5 are given. **b** The efficiency of the depletion of CD8<sup>+</sup> T cells in Fig. 4e is shown in representative FACS plots from blood samples two days after the injection of the depleting antibody or control.